904316-35-4 Purity
96%
If you have any other questions or need other size, please get a quote.
Specification
Reference: [1]Current Patent Assignee: DAIICHI SANKYO COMPANY, LIMITED - US2010/130492, 2010, A1
Location in patent: Page/Page column 93
[2]Current Patent Assignee: UCB - WO2016/124508, 2016, A1
Location in patent: Page/Page column 43
[3]Current Patent Assignee: NOVARTIS AG; Novartis (w/o Sandoz) - WO2007/84786, 2007, A1
Location in patent: Page/Page column 90-91
[4]Burger, Matthew T.; Knapp, Mark; Wagman, Allan; Ni, Zhi-Jie; Hendrickson, Thomas; Atallah, Gordana; Zhang, Yanchen; Frazier, Kelly; Verhagen, Joelle; Pfister, Keith; Ng, Simon; Smith, Aaron; Bartulis, Sarah; Merrit, Hanne; Weismann, Marion; Xin, Xiaohua; Haznedar, Joshua; Voliva, Charles F.; Iwanowicz, Ed; Pecchi, Sabina
[ACS Medicinal Chemistry Letters, 2011, vol. 2, # 1, p. 34 - 38]
[5]Current Patent Assignee: DANA-FARBER CANCER INSTITUTE - WO2012/109423, 2012, A1
Location in patent: Page/Page column 19
Reference: [1]Current Patent Assignee: DAIICHI SANKYO COMPANY, LIMITED - US2010/130492, 2010, A1
Location in patent: Page/Page column 90
* For details of the synthesis route, please refer to the original source to ensure accuracy.